Long‐term prognosis of patients with alcoholic liver cirrhosis: a 15‐year follow‐up study of 100 Norwegian patients admitted to one unit

Bell, Hollis K.; Jahnsen, Jørgen; Kittang, E; Raknerud, N; Sandvik, Leiv

doi:10.1080/00365520410006350

Cited by 93 publications

(93 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with alcoholic liver cirrhosis developed more often and more severely ascites than cases with nonalcoholc liver cirrhosis. Two different study (Danish and Norwegian) evidenced ascites as the leading initial hepatic decompensation in 55% and 67% of cases respectively [10,11,15]. Also a Spanish study observed higher rates of ascites in alcoholic cirrhosis (59 %) [17].…”

Section: Discussionmentioning

confidence: 99%

Different Models of Decompensation in Alcoholic versus Nonalcoholic Cirrhotic Patients

2015

IJSR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Different Models of Decompensation in Alcoholic versus Nonalcoholic Cirrhotic Patients

2015

IJSR

View full text Add to dashboard Cite

“…The mortality in patients with advanced alcoholic cirrhosis was extremely high (5 years 71 %, 15 years 90 %) [74]. High age and continuous alcohol consumption of more than 10 g ethanol per day were independent predictors of a poor prognosis [74]. The prognostic importance of abstinence was demonstrated in both Child-Pugh A/B and Child-Pugh C patients [75].…”

Section: Antifibrotic Therapymentioning

confidence: 97%

“…Continued heavy drinking was associated with poor survival of cirrhotic patients [73]. The mortality in patients with advanced alcoholic cirrhosis was extremely high (5 years 71 %, 15 years 90 %) [74]. High age and continuous alcohol consumption of more than 10 g ethanol per day were independent predictors of a poor prognosis [74].…”

Section: Antifibrotic Therapymentioning

confidence: 99%

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V 2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

show abstract

“…Five of the seven studies set a cut-off of at least 80g/day. [4][5][6][7][8] Since our patient would not qualify for those studies, we can exclude them. Of the remaining two studies, Powell et al only specifies that subjects had a history of chronic alcoholism, and Alvarez et al specifies at least 80g/day in men and 60g/day in women.…”

Section: Related Literaturementioning

confidence: 99%

Abstinence from alcohol improves survival in decompensated cirrhotic patients

Zong

2018

Clin. Res. Pract.

View full text Add to dashboard Cite

Long‐term prognosis of patients with alcoholic liver cirrhosis: a 15‐year follow‐up study of 100 Norwegian patients admitted to one unit

Cited by 93 publications

References 11 publications

Different Models of Decompensation in Alcoholic versus Nonalcoholic Cirrhotic Patients

Different Models of Decompensation in Alcoholic versus Nonalcoholic Cirrhotic Patients

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Abstinence from alcohol improves survival in decompensated cirrhotic patients

Contact Info

Product

Resources

About